Evidence map›Paper›PMID 35328787›Full record

ReviewInternational journal of molecular sciences2022

Radiobiological and Treatment-Related Aspects of Spatially Fractionated Radiotherapy.

Leyla Moghaddasi, Paul Reid, Eva Bezak, Loredana G Marcu

Registry-linked trialAbstract readReview
In one paragraph

Review in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06980259 (Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma), which is not on this map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06980259 narecruitingnot on this mapstarted 2025, after this paper: background citation

Spatially Fractionated Radiotherapy Versus Conventional Radiotherapy in the Treatment of Soft Tissue Sarcoma:A Multicenter,Prospective, Phase II, Randomized Controlled Trial

TypeinterventionalSponsorShandong Cancer Hospital and InstituteRan2025 to 2028Enrolled106ConditionsSoft Tissue Sarcoma (STS)ArmsSpatially Fractionated Radiotherapy, Conventional Radiotherapy
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Proton minibeam radiotherapy: a review.Frontiers in oncology · 2025
    Review
  11. Article
  12. Review
  13. Review
  14. Article
  15. Article
  16. Article
  17. Translational Frontiers and Clinical Opportunities of Immunologically Fitted Radiotherapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Leyla MoghaddasiDepartment of Medical Physics, Austin Health, Ballarat, VIC 3350, Australia.ORCID 0000-0001-6127-912X
Paul ReidRadiation Health, Environment Protection Authority, Adelaide, SA 5000, Australia.
Eva BezakSchool of Physical Sciences, University of Adelaide, Adelaide, SA 5001, Australia.ORCID 0000-0002-1315-1735
Loredana G MarcuCancer Research Institute, University of South Australia, Adelaide, SA 5001, Australia.ORCID 0000-0002-6703-979X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The continuously evolving field of radiotherapy aims to devise and implement techniques that allow for greater tumour control and better sparing of critical organs. Investigations into the complexity of tumour radiobiology confirmed the high heterogeneity of tumours as being responsible for the often poor treatment outcome. Hypoxic subvolumes, a subpopulation of cancer stem cells, as well as the inherent or acquired radioresistance define tumour aggressiveness and metastatic potential, which remain a therapeutic challenge. Non-conventional irradiation techniques, such as spatially fractionated radiotherapy, have been developed to tackle some of these challenges and to offer a high therapeutic index when treating radioresistant tumours. The goal of this article was to highlight the current knowledge on the molecular and radiobiological mechanisms behind spatially fractionated radiotherapy and to present the up-to-date preclinical and clinical evidence towards the therapeutic potential of this technique involving both photon and proton beams.

Indexed as

NeoplasmsRadiation OncologyDose Fractionation, RadiationHumansPhotonsRadiobiologyRadiotherapyGRID radiotherapynon-conventional radiotherapyorgan sparingprotonstherapeutic index

Identifiers

PMID35328787
PMCPMC8954016

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.